Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Lactose (India) Ltd (LACTOSE) is currently trading at 90.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lactose (India) Ltd is a manufacturing and trading company in the pharmaceutical sector, specializing in edible and pharmaceutical-grade lactose alongside dairy products. The company has undertaken significant expansions, increasing lactose production capacity substantially from 465 tpa to 1500 tpa within a few years. Partnerships with major companies like Dr Reddy’s and Kerry Group have elevated its market stance, particularly in contract manufacturing. Recent ventures into manufacturing Lactulose and lactose mono-hydrate show strategic moves toward broader product offerings and increased self-marketing. The Vadodara-based state-of-the-art facilities comply with international standards, supporting both domestic sales and exports, enhancing its competitive edge.
Over the past 52 weeks, Lactose (India) Ltd has traded between a low of ₹84.27 and a high of ₹136.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lactose (India) Ltd has a market capitalization of approximately 119.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lactose (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.09 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 119.56 Cr, Lactose (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lactose (India) Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lactose (India) Ltd is 24.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
4
Bullish
6
Bearish
36
Neutral
4
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Lactose (India) Ltd is a manufacturing and trading company in the pharmaceutical sector, specializing in edible and pharmaceutical-grade lactose alongside dairy products.
The company has undertaken significant expansions, increasing lactose production capacity substantially from 465 tpa to 1500 tpa within a few years.
Partnerships with major companies like Dr Reddy’s and Kerry Group have elevated its market stance, particularly in contract manufacturing.
Recent ventures into manufacturing Lactulose and lactose mono-hydrate show strategic moves toward broader product offerings and increased self-marketing.
The Vadodara-based state-of-the-art facilities comply with international standards, supporting both domestic sales and exports, enhancing its competitive edge.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
120 Cr
Low Risk
24.1
57.0
0.9
1.9
136.70
84.27
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
130.50 | 145 Cr | 32.54 | 2.04 | 1.19 | 6.60 | 10.56 | 4.61 | |
30.10 | 143 Cr | 15.76 | 12.31 | 0.00 | 70.62 | 33.57 | 8.92 | |
105.50 | 139 Cr | 11.30 | 1.01 | 0.76 | 8.89 | 11.28 | 7.21 | |
90.10 | 120 Cr | 24.09 | 1.92 | 0.00 | 7.24 | 10.49 | 3.50 | |
55.05 | 119 Cr | -5.19 | 0.00 | 0.00 | 14.21 | -14.91 | -13.78 | |
91.52 | 113 Cr | 8.10 | 1.06 | 0.00 | 9.10 | 12.39 | 10.91 | |
107.05 | 110 Cr | 16.12 | 0.78 | 2.80 | 6.85 | 9.26 | 4.35 |
